Subscribe for real-time financial insights on Trade Target’s WhatsApp Channels
Quick Summary
Hexagon Nutrition IPO GMP Overview: Investors can bid for the ₹138.87 crore Hexagon Nutrition IPO from 5 June to 9 June 2026. The issue is priced in the range of ₹42 to ₹45 per share. Following the closure of the issue, allotment is likely on 10 June, with a tentative listing date of 12 June 2026 on both BSE and NSE. Meanwhile, the IPO’s grey market premium showed no premium as of 31 May 2026.
Hexagon Nutrition IPO GMP Live Rates Day by Day
Hexagon Nutrition IPO GMP today (31st June 2026) stands at ~0%. GMP values change daily and we’ll keep you updated with the latest figures.
GMP figures are for news purposes only. We neither trade nor recommend trading in the grey market. GMP data is taken from multiple media reports
| GMP Date | IPO Price | GMP | Estimated Listing Price | Estimated Profit |
| 31-06-2026 | ₹45 | ₹0 | ₹45 (0%) | ₹0 |
Hexagon Nutrition IPO Details
- Hexagon Nutrition IPO is a ₹138.87 crore public issue and is entirely of an Offer for Sale (OFS), with no fresh issue of shares.
- The IPO will remain open for subscription from 5 June to 9 June 2026. And the company has fixed the price band at ₹42–₹45 per share.
- Allotment is expected to be finalised on 10 June 2026, while the shares are likely to be listed on BSE and NSE on 12 June 2026.
- Hexagon promoters currently hold an 89.41% stake in the company. Post listing, their shareholding is expected to decline to 64.29%. Hexagon Nutrition’s estimated market capitalisation stands at around ₹553.13 crore.
- KFin Technologies has been appointed as the registrar to the issue
Hexagon Nutrition IPO Dates
Here are some important dates for the upcoming IPO of Hexagon Nutrition.
| IPO Open Date | 5 Jun 2026 |
| IPO Close Date | 9 June 2026 |
| IPO Allotment Date | 10 June 2026 |
| Initiation of Refunds | 11 June 2026 |
| Demat Credits | 11 June 2026 |
| Listing Date | 12 June 2026 |
| Listing on | BSE, NSE |
Hexagon Nutrition IPO Reservation
For Hexagon Nutrition IPO, 35% has been reserved for retail investors.
| Investor Category | Shares Offered |
| QIB Investors | 50% |
| Retail Investors | 35% |
| NII (HNI) Investors | 15% |
Hexagon Nutrition IPO Lot Size
Retail investors can bid for at least one lot, including 333 shares. At the upper price band of ₹45 per share, the minimum investment will be ₹14,985. Retail applicants can subscribe to a maximum of 13 lots, equivalent to 4,329 shares. The maximum investment amount at the upper price band is ₹1,94,805.
| Application | Lots | Shares | Amount |
| Retail (Min) | 1 | 333 | ₹14,985 |
| Retail (Max) | 13 | 4,329 | ₹1,94,805 |
| S-HNI (Min) | 14 | 4,662 | ₹2,09,790 |
| S-HNI (Max) | 66 | 21,978 | ₹9,89,010 |
| B-HNI (Min) | 67 | 22,311 | ₹10,03,995 |
About Hexagon Nutrition IPO
Founded in 1993, Hexagon Nutrition is engaged in development and manufacturing of nutrition and wellness products. The company caters to both consumer and institutional markets through its portfolio of clinical nutrition products, micronutrient premixes, and fortified food solutions.
Hexagon Nutrition operates manufacturing facilities in India and also has an international plant in Tashkent, Uzbekistan. Its business is spread across consumer nutrition brands, customised premix solutions for businesses, and nutrition products designed for public health and ESG-driven programs.
The company’s product portfolio includes brands such as Pentasure, Obesigo, Pediagold, and Nutrone. Between FY23 and FY25, it supplied products to over 75 countries across multiple regions. As of 31 March 2026, Hexagon Nutrition had a workforce of 527 employees.
Hexagon Nutrition Financial Performance
Hexagon Nutrition’s profit after tax (PAT) increased to ₹24 crore in FY25 from ₹12 crore in FY24, continuing its growth trend over the past three years. Key financial metrics are shown in the table below.
| Period Ended | 31 Mar 2025 | 31 Mar 2024 | 31 Mar 2023 |
| Revenue from Ops (₹ Cr) | 324.93 | 297.73 | 278.50 |
| Total Income (₹ Cr) | 331.29 | 304.62 | 281.65 |
| EBITDA (₹ Cr) | 40.07 | 24.88 | 17.17 |
| EBITDA Margin (%) | 12.33% | 8.36% | 6.17% |
| PAT (₹ Cr) | 24.38 | 12.21 | 5.82 |
| PAT Margin (%) | 7.36% | 4.01% | 2.07% |
| ROE (%) | 10.47% | 7.21% | 3.50% |
| ROCE (%) | 17.06% | 11.12% | 5.94% |
| Debt-to-Equity Ratio | 0.14 | 0.21 | 0.3 |
Source: Hexagon Nutrition RHP
Hexagon Nutrition IPO Peer Comparison from RHP
Compared with its industry peers, Hexagon Nutrition reports a relatively lower diluted EPS. Investors use EPS as a key measure of profitability and shareholder value. A comparison is presented below.
| Company | Revenue from Operations (₹ Cr) as of 31 March | EPS (Diluted, ₹) | P/E (x) |
| Hexagon Nutrition | 324.93 | 1.75 | – |
| Zydus Wellness | 2,780.90 | 10.90 | 46.22 |
| Nestlé India | 20,201.56 | 16.63 | 88.86 |
FAQs on Hexagon Nutrition IPO GMP
What is the latest GMP of Hexagon Nutrition IPO?
As of 31 May 2026, the grey market premium of Hexagon Nutrition IPO is ₹0, indicating no premium in the unofficial market.
What listing gains can investors expect from Hexagon Nutrition IPO?
With the GMP currently at ₹0, there is no indication of listing gains at present. However, GMP can fluctuate before the IPO closes and listing approaches.
What are the subscription dates for Hexagon Nutrition IPO?
The public issue will open for bidding on 5 June 2026 and close on 9 June 2026.
What is the minimum investment required in Hexagon Nutrition IPO?
Retail investors can apply for one lot comprising 333 shares. At the lower price band of ₹42 per share, the minimum investment amount is ₹13,986.
When is the allotment expected for Hexagon Nutrition IPO?
The basis of allotment is likely to be finalised on 10 June 2026.
Who is managing the allotment process for the IPO?
KFin Technologies Limited has been appointed as the registrar to the issue.
Should investors consider applying for Hexagon Nutrition IPO?
Investors may evaluate the IPO based on factors such as the company’s improving profitability, consistent earnings growth, and financial ratios like ROE and ROCE, along with their own risk appetite and investment objectives.
